Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Plasma cell 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 363Precursor Cell Lymphoblastic Leukemia-Lymphoma 89Leukemia 61Neoplasms, Plasma Cell 60Lymphoma 59Recurrence 52Neoplasms 34Vomiting 33Lymphoma, Non-Hodgkin 32Immunoglobulin Light-chain Amyloidosis 27Lymphoma, Mantle-Cell 26Burkitt Lymphoma 26Nausea 22Lymphoma, Large B-Cell, Diffuse 21Leukemia, Lymphocytic, Chronic, B-Cell 21Waldenstrom Macroglobulinemia 19Prostatic Neoplasms 19Lymphoma, Follicular 18Hodgkin Disease 18Neoplasm Metastasis 14Breast Neoplasms 14Amyloidosis 12Lymphoma, B-Cell, Marginal Zone 11Leukemia, Myeloid, Acute 11Carcinoma, Non-Small-Cell Lung 11Ovarian Neoplasms 9Lymphoma, Large-Cell, Immunoblastic 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell, Cutaneous 8Colonic Neoplasms 8

Interventions

dacetuzumab 5blinatumomab 4Bortezomib 4Lenalidomide 3Dexamethasone 3Rituximab 2tetulomab tetraxetan lu-177 1ponatinib 1pembrolizumab 1pegaspargase 1isatuximab 1ibrutinib 1ficlatuzumab 1durvalumab 1asparaginase erwinia chrysanthemi recombinant 1acalabrutinib 1Vorinostat 1Methotrexate 1Lutetium 1KW-2478 1Ifosfamide 1Hsp90 inhibitor KU757 1Gemcitabine 1Erlotinib Hydrochloride 1Daunorubicin 1Cyclophosphamide 1Calcium Dobesilate 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Immunoproliferative Disorders × Dexamethasone × Clear all
NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

University of Heidelberg Medical Center

Phase 3 Completed
514 enrolled
LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00525447 2014-10-09

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

Seagen Inc.

Phase 1 Completed
36 enrolled
LymphoidPlasma cell

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡